Methylation of p15 and p16 genes in acute promyelocytic leukemia: Potential diagnostic and prognostic significance

Journal of Clinical Oncology

Volumn 19, Issue 7, 2001, Pages 2033-2040

  Chim, J C S ^a   Liang, R ^a   Tam, C Y Y ^a   Kwong, Y L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P15; PROTEIN P16;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL TIME;

EID: 0035300727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.7.2033     Document Type: Article

References (43)

1. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
2. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
3. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
4. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL)
5. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
6. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
7. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
8. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction
9. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
10. Role of the cyclin-dependent kinase inhibitors in the development of cancer
11. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers
12. DNA methylation
13. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B
14. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
15. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
16. Mutational analysis of the p15 and p16 genes in acute leukaemias
17. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines
18. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia
19. Aberrant p15 promotor methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: Potential prognostic implications
20. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia
21. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia
22. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group
23. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chooroform extraction
24. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
25. Nonparametric estimation from incomplete observations
26. Regression models and life-tables
27. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features
28. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
29. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia
30. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia
31. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma
32. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
33. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
34. Methylation of the p15(IK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression
35. The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL
36. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment responses
37. Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance
38. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival
39. Prognostic importance of p15INK4B and p16INK4a gene inactivation in childhood acute lymphoblastic leukemia
40. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy: Japan Adult Leukemia Study Group
41. All-trans-retinoic acid in acute promyelocytic leukemia
42. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC Trial
43. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia: PETHEMA group